Clinical Trials Logo

Filter by:
NCT ID: NCT04124783 Withdrawn - Menopause Symptoms Clinical Trials

Study to Evaluate the Effects of the Cooling Bolero in Women With Menopause Symptoms

Start date: October 23, 2019
Phase: N/A
Study type: Interventional

The Cooling Bolero is a vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbed heat. The vest is manufactured by Nanohealth. It intended to provide moderate cooling (~15C/59F) through indirect contact with the skin. The material in the device is safe, non-toxic, and eco-friendly. Recent anecdotal studies of women with common peri-menopausal and menopausal symptoms (hot flashes, night sweats, flushing/sweating of face and neck, and intermittent sleep disturbances) have shown a reduction in both the frequency and intensity of those symptoms after using the Cooling Bolero. Specific (moderate) temperature cooling of the neck and upper torso appears to target and mitigate these common menopausal symptoms. This pilot study attempts to collect additional data on the effects of the Cooling Bolero.

NCT ID: NCT04123574 Withdrawn - Pancreatic Cancer Clinical Trials

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

Start date: October 15, 2019
Phase: Early Phase 1
Study type: Interventional

A study to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.

NCT ID: NCT04123483 Withdrawn - Clinical trials for Premenstrual Syndrome

EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders

Start date: November 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess a novel nutritional supplement developed for prenatal health and mood benefits, and to determine whether there is preliminary evidence for efficacy in Menstrual Related Mood Disorders (MRMD), including PMS with Prominent Mood Symptoms and PMDD.

NCT ID: NCT04121299 Withdrawn - Masked Hypertension Clinical Trials

Mechanism of Masked Hypertension - Intervention

Start date: July 2021
Phase: Phase 3
Study type: Interventional

To test the hypothesis that sympatholytic antihypertensive antihypertensive therapy (αβ-blocker - carvedilol) will reduce out-of-clinic ambulatory BP to a greater extent by blocking sympathetic activity than non-sympatholytic antihypertensive medication (dihydropyridine calcium channel blocker - amlodipine) in individuals with masked hypertension.

NCT ID: NCT04120987 Withdrawn - Dry Eye Clinical Trials

Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra

Start date: May 31, 2021
Phase: Phase 4
Study type: Interventional

To determine if the use of Xiidra® reduces ocular surface inflammation in preoperative and postoperative cataract patients.

NCT ID: NCT04119830 Withdrawn - Clinical trials for Stage IV Colorectal Cancer AJCC v8

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Start date: February 1, 2022
Phase: Phase 2
Study type: Interventional

This phase IIa trial studies how well rintatolimod and pembrolizumab works in treating patients with colorectal cancer that does not respond to treatment (refractory), has spread to other places in the body (metastatic), or otherwise cannot be removed by surgery (unresectable). Rintatolimod is an immuno-oncology agent that can stimulate the immune system. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving rintatolimod and pembrolizumab together may work better than standard of care in treating patients with colorectal cancer.

NCT ID: NCT04118036 Withdrawn - Glioblastoma Clinical Trials

Abemaciclib + Pembrolizumab In Glioblastoma

Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. This study will involve participants with recurrent glioblastoma at their first relapse enrolled in two arms including patients who require reoperation and patients not requiring surgery. This research study involves a combination of two drugs: - Pembrolizumab (MK3475) - Abemaciclib (LY2835219)

NCT ID: NCT04117438 Withdrawn - Breast Neoplasms Clinical Trials

Tell us Your Food Story

Start date: October 1, 2019
Phase:
Study type: Observational

In 2017, it is estimated that 318,590 Americans, men and women, will be diagnosed with breast cancer (American Cancer Society, 13). It was predicted in the 1970s that 1 in 11 Americans would be diagnosed with breast cancer, currently, it is 1 in 8 people. A person is twice as likely to be diagnosed with breast cancer if they have one first-degree female with a diagnosis, 3-4 times if there is more than one first-degree female relative with a diagnosis. Reasons for this increase in breast cancer diagnoses are that people are living longer, changes in reproductive patterns, increases or decreases in menopausal hormone use, increased numbers of detection through screening including genetic testing, and the rising prevalence of obesity (American Cancer Society). The purpose of this study is to better understand how a diagnosis of breast cancer supports change in diet and their food story. Qualitative methodology and specifically the long interview is the method the team will use to gain insight into adult patients' perceptions of their food story.

NCT ID: NCT04117373 Withdrawn - Skin Cancer Clinical Trials

Mohs Micrographic Surgery and Reconstruction in the Optum Insurance Claims Database

Start date: July 1, 2019
Phase:
Study type: Observational

Mohs micrographic surgery (MMS) followed by skin reconstruction has been widely accepted for treatment of many skin cancers. To further characterize the trends in MMS and reconstruction for skin cancer, a retrospective analysis will be performed using the Optum© Clinformatics® DataMart de-identified commercial claims database from 2001-2016. The findings may provide critical data for future prospective studies in skin cancer treatments.

NCT ID: NCT04115501 Withdrawn - Lung Injury Clinical Trials

Intra-operative Fraction of Inspired Oxygen and Lung Injury in Coronary Artery Bypass Grafting Surgery

Start date: February 27, 2021
Phase: N/A
Study type: Interventional

This study is a prospective observer blinded, central randomization controlled, multi-center clinical trial to assess the relationship between intraoperative FiO2 and postoperative pulmonary complications with lung injury.